Humacyte Secures $60 Million in Oversubscribed Offering to Advance Bioengineered Tissue Platform

Humacyte, Inc. (NASDAQ: HUMA) has entered into a securities purchase agreement with fundamental institutional investors for an oversubscribed registered direct offering totaling approximately $60 million. The commercial-stage biotechnology platform company, which develops universally implantable, bioengineered human tissues, will issue 28,436,018 shares of common stock and accompanying warrants to purchase an equal number of shares at $2.11 per unit. The warrants become exercisable 180 days after issuance, carry an exercise price of $2.11 per share, and expire April 7, 2031.

Gross proceeds are expected to total $60 million before fees and expenses, with closing anticipated on or about October 8, 2025. D. Boral Capital LLC is acting as exclusive placement agent for the offering. The oversubscribed nature of this financing demonstrates strong institutional confidence in Humacyte's technology platform and commercial prospects at a critical juncture in the company's development.

This capital infusion comes shortly after Humacyte achieved a significant regulatory milestone with the Food and Drug Administration's approval of its Biologics License Application for the acellular tissue engineered vessel in extremity vascular trauma in December 2024. The company's vascular technology platform represents a potentially transformative approach to tissue engineering and regenerative medicine. Additional information about the company's technology platform is available at https://humacyte.com/.

Humacyte's pipeline includes multiple advanced clinical programs targeting substantial medical needs. The company's 6mm acellular tissue engineered vessel for arteriovenous access in hemodialysis was the first product candidate to receive the FDA's Regenerative Medicine Advanced Therapy designation and has also received FDA Fast Track designation. The same technology for urgent arterial repair following extremity vascular trauma and for advanced peripheral artery disease have also received RMAT designations, highlighting the platform's broad potential applications.

The funding arrives as Humacyte advances late-stage clinical trials for additional vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. The company's technology has received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense, underscoring its potential importance for military medicine and trauma care.

This substantial financial backing positions Humacyte to accelerate the development and potential commercialization of its bioengineered tissue platform across multiple therapeutic areas. The successful offering reflects investor recognition of the company's progress in advancing a potentially disruptive biotechnology platform that could address significant unmet medical needs in vascular repair and regeneration. The capital will support ongoing clinical development, manufacturing scale-up, and preparation for potential commercial launches across multiple indications.